MCF2L2: A Potential Drug Target for Myosin ATPase and Cancer (G23101)
MCF2L2: A Potential Drug Target for Myosin ATPase and Cancer
Guanine nucleotide exchange factors (GNEs) are a family of proteins that play a crucial role in intracellular signaling. The Rho family of GNPs is a well-established family of N-terminal GNEs that are involved in various cellular processes, including cell division, cytoskeletal organization, and cell-cell interactions. One of the Rho family GNPs, called MCF2L2 (middle C-terminal GNE), has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders.
MCF2L2 function
MCF2L2 is a 21-kDa protein that is expressed in various tissues, including brain, heart, and skeletal muscles. It is a member of the Rho family GNP and is characterized by its N-terminal region containing a nucleotide-binding oligomerization domain (NBO), a conserved protein-coding region, and a C-terminal region that contains a unique GFP-like fluorescent tag. The NBO domain is known to function as a protein-protein interaction (PPI) domain and is involved in the regulation of various cellular processes, including cell division, cytoskeletal organization, and intracellular signaling pathways.
MCF2L2 is involved in several cellular processes that are crucial for normal cellular function. One of its functions is to regulate the assembly and disassembly of microtubules, which are important for cell division and cytoskeletal organization. Additionally, MCF2L2 is involved in the regulation of the actinin cytoskeleton, which is important for cell movement and mechanical forces.
MCF2L2 is also involved in the regulation of various signaling pathways, including the Rho GTPase pathway. This pathway is involved in the regulation of cell division, cytoskeletal organization, and intracellular signaling pathways. The Rho GTPase is a protein that is involved in the regulation of the Rho GTPase complex, which is a key component of the Rho pathway. The Rho pathway is a well-established pathway that is involved in the regulation of various cellular processes, including cell division, cytoskeletal organization, and intracellular signaling pathways.
MCF2L2 is also involved in the regulation of the myosin ATPase (Myosin Light Chain 2) gene, which encodes the protein Myosin Light Chain 2 (MLC2). MLC2 is a key component of the myosin ATPase complex, which is involved in the regulation of muscle contractions and relaxation.
MCF2L2 functions as a negative regulator of the myosin ATPase gene
MCF2L2 is involved in the regulation of the myosin ATPase (Myosin Light Chain 2) gene, which encodes the protein Myosin Light Chain 2 (MLC2). MLC2 is a key component of the myosin ATPase complex, which is involved in the regulation of muscle contractions and relaxation.
Studies have shown that MCF2L2 functions as a negative regulator of the myosin ATPase gene. This can be determined by various methods, including RNA interference, overexpression, and protein array analysis. These studies have shown thatMCF2L2 can inhibit the myosin ATPase gene by binding to its mRNA and preventing its translation into protein.
MCF2L2 is also involved in the regulation of the myosin ATPase (Myosin Light Chain 2) gene, which encodes the protein Myosin Light Chain 2 (MLC2). MLC2 is a key component of the myosin ATPase complex, which is involved in the regulation of muscle contractions and relaxation.
MCF2L2 is a potential drug target or biomarker
The Rho family of GNPs is a well-established family of proteins that are involved in various cellular
Protein Name: MCF.2 Cell Line Derived Transforming Sequence-like 2
Functions: Probably functions as a guanine nucleotide exchange factor
The "MCF2L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MCF2L2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MCFD2 | MCFD2P1 | MCHR1 | MCHR2 | MCHR2-AS1 | MCIDAS | MCL1 | MCM10 | MCM2 | MCM3 | MCM3AP | MCM3AP-AS1 | MCM4 | MCM5 | MCM6 | MCM7 | MCM8 | MCM8-MCM9 complex | MCM9 | MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex
